Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PureTech HealthCHIX:PRTCL -5.11%61 Shiller PE Ratio is 30.15 as of Sep. 02, 2026, which is 32% below its 10-year median of 44.10. GuruFocus rates CHIX:PRTCL with a GF Score™ of 61/100 and a GF Value™ of £5.46 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 171 Biotechnology companies, PureTech Health ranks better than 54.97% on this metric.
As of today (2026-09-02), PureTech Health's current share price is £1.206. PureTech Health's E10 for the fiscal year that ended in Dec25 was £0.04. PureTech Health's Shiller PE Ratio for today is 30.15.
The historical rank and industry rank for PureTech Health's Shiller PE Ratio or its related term are showing as below:
CHIX:PRTCl'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.76 Med: 44.1 Max: 117
Current: 29.74
During the past 13 years, PureTech Health's highest Shiller PE Ratio was 117.00. The lowest was 22.76. And the median was 44.10.
CHIX:PRTCl's Shiller PE Ratio is ranked better than 54.97% of 171
companies
in the Biotechnology industry
Industry Median: 32.7
vs CHIX:PRTCl: 29.74
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
PureTech Health's adjusted earnings per share data of for the fiscal year that ended in Dec25 was £-0.344. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is £0.04 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
PureTech Health (CHIX:PRTCl) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
PureTech Health Shiller PE Ratio Related Terms
PureTech Health Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for PureTech Health's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRTCL vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison
For the Biotechnology subindustry, PureTech Health's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where PureTech Health's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
PureTech Health's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health's E10 for the fiscal year that ended in Dec25 is calculated as:
For example, PureTech Health's adjusted earnings per share data for the fiscal year that ended in Dec25 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
PureTech Health (CHIX:PRTCL) has a Shiller PE Ratio of 30.15 as of Sep. 02, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on PureTech Health and its competitors. This is 32% below median its historical median of 44.10. Over the past decade, PureTech Health's Shiller PE Ratio has ranged from 22.76 to 117.00. According to the industry distribution chart, PureTech Health ranks #77 out of 171 companies in the Biotechnology industry, placing it in the top 45%.
Is PureTech Health's Shiller PE Ratio too high?
PureTech Health's current Shiller PE Ratio of 30.15 is 32% below median its 10-year median of 44.10. Over the past 10 years, this metric has ranged from a low of 22.76 to a high of 117.00. The Biotechnology industry median Shiller PE Ratio is 32.70. PureTech Health's value of 30.15 is 7.8% below this industry median. Based on the distribution chart, PureTech Health ranks #77 out of 171 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Shiller PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #77 out of 171 companies for Shiller PE Ratio. This puts PureTech Health in the upper half of its industry. The industry median Shiller PE Ratio is 32.70. PureTech Health's value of 30.15 is 7.8% below this benchmark. Historically, PureTech Health's own Shiller PE Ratio has ranged from 22.76 to 117.00 over the past decade. While the company's 10-year median is 44.10 vs. the industry median of 32.70, PureTech Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 32.70, based on 171 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Shiller PE Ratio of 30.15 is 7.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 32.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Shiller PE Ratio is 30.15, which is 32% below median its own 10-year median of 44.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.46, compared to a current price of £1.21 — trading 77.9% below its estimated fair value. The current Shiller PE Ratio is 30.15, which is 32% below median its 10-year median of 44.10 and 7.8% below the Biotechnology industry median of 32.70. PureTech Health's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current Shiller PE Ratio is 30.15 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.21 is trading 77.9% below its estimated GF Value™ of £5.46.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for CHIX:PRTCL:
Shiller PE Ratio: 30.15 (32% below median its 10-year median of 44.10)
GF Value™: £5.46 vs. price of £1.21 (77.9% below fair value)
Industry Position: 7.8% below the Biotechnology median (#77 of 171)
No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
61GF Score
Get the complete analysis for CHIX:PRTCL
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRTCL has been successfully added to your 
